EMA/PE/0000182607 - paediatric investigation plan

Maribavir

Key facts

• Invented name:
  Livtencity
• Active substance:
  Maribavir
• Therapeutic area:
  Infections and infestations
• Decision number:
  EMA/PE/0000182607
• PIP number:
  EMA/PE/0000182607
• Pharmaceutical form(s):
  • Film-coated tablet
  • Powder for oral suspension
• Condition(s) / indication(s):
  Treatment of cytomegalovirus (CMV) infection
• Route(s) of administration:
  Oral use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  03/01/2025
• Compliance check done:
  No

Decision

EMA/PE/0000182607 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for maribavir (Livtencity)

Adopted Reference Number: EMADOC-1700519818-1811036